Clearmind Medicine sets 1-for-10 reverse stock split effective May 21, 2026
No insider trades found for CMND.
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | $69.19K | $71.09K | $79.06K | $119.62K | $2.53K | N/A | N/A | N/A |
| Gross Profit | $-69.19K | $-71.09K | $-79.06K | $-119.62K | $-2.53K | N/A | N/A | N/A |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $7.87M | $7.93M | $8.59M | $8.88M | $3.61M | $230.12K | $104.15K | $259.19K |
| Operating Income | $-7.94M | $-8.00M | $-8.67M | $-9.00M | $-3.61M | $-230.12K | $-104.15K | $-259.19K |
| Operating Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income | $-5.41M | $-7.31M | $-11.85M | $-9.93M | $-3.66M | $-230.12K | $-104.15K | $-198.09K |
| Net Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-42.53 | $-94.38 | $-2341.32 | $-9164.43 | $-4731.05 | $-507.60 | $-337.61 | $-735.01 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |